Viatris
Viatris returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
Invested capital did not increase versus the prior year. ROIIC requires a positive increase.
ROE
% · Annual / TTM
The reported inputs required for this metric are unavailable in the extracted statements for this period.
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | — | -0.29% | — | — | — | — |
| FY 2026 Q1 | Mar 31, 2026 | — | 0.44% | — | — | — | — |
| FY 2025 Q4 | Dec 31, 2025 | — | -8.09% | — | — | -8.93% | — |
| FY 2025 Q3 | Sep 30, 2025 | — | -7.82% | — | — | — | — |
| FY 2025 Q2 | Jun 30, 2025 | — | -7.56% | — | — | — | — |
| FY 2025 Q1 | Mar 31, 2025 | — | -8.5% | — | — | — | — |
| FY 2024 Q4 | Dec 31, 2024 | — | 0.03% | — | — | -1.42% | — |
| FY 2024 Q3 | Sep 30, 2024 | — | -0.67% | — | — | — | — |
| FY 2024 Q2 | Jun 30, 2024 | — | -0.1% | — | — | — | — |
| FY 2024 Q1 | Mar 31, 2024 | — | 1.38% | — | — | — | — |
| FY 2023 Q4 | Dec 31, 2023 | 0.54% | 1.84% | — | — | 0.11% | -7.4 pp |
| FY 2023 Q3 | Sep 30, 2023 | 1.95% | 2.43% | — | — | — | -6 pp |
| FY 2023 Q2 | Jun 30, 2023 | 2.1% | 2.63% | — | — | — | -5.8 pp |
| FY 2023 Q1 | Mar 31, 2023 | 2.38% | 3.01% | — | — | — | -5.5 pp |
| FY 2022 Q4 | Dec 31, 2022 | 2.97% | 3.66% | — | — | 3.96% | -4.9 pp |
| FY 2022 Q3 | Sep 30, 2022 | 3.06% | 3.95% | — | — | — | -4.8 pp |
| FY 2022 Q2 | Jun 30, 2022 | 3.1% | 3.37% | — | — | — | -4.8 pp |
| FY 2022 Q1 | Mar 31, 2022 | 1.2% | 2.02% | — | — | — | -6.7 pp |
| FY 2021 Q4 | Dec 31, 2021 | — | -0.07% | — | — | -2.18% | — |
| FY 2021 Q3 | Sep 30, 2021 | — | — | — | — | — | — |
| FY 2021 Q2 | Jun 30, 2021 | — | — | — | — | — | — |
| FY 2021 Q1 | Mar 31, 2021 | — | — | — | — | — | — |
| FY 2020 Q4 | Dec 31, 2020 | — | — | — | — | — | — |
| FY 2020 Q3 | Sep 27, 2020 | — | — | — | — | — | — |
| FY 2020 Q2 | Jun 28, 2020 | — | — | — | — | — | — |
| FY 2020 Q1 | Mar 29, 2020 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · VTRS, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.